Pivanex

Research use only, not for human use.

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.(In Vitro):In K562 cells, Pivanex (100-500 μM) exhibits significant anti-proliferation activity and enhances apoptosis and caspase activity. Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle.(In Vivo):Pivanex(200 mg/kg, b.i.d, daily) treatment marked delays in the end stage of disease as defined by the onset of body mass loss by 94.9%. Pivanex(200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice by 84.6%.

Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.Pivanex (200 μM)induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Cell Viability Assay Cell Line:K562 cells.Concentration:100-500 μM.Incubation Time:24 hours.Result:Reduced the number of K562 viable cells significantly.100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically.Apoptosis Analysis Cell Line:K562 cells.Concentration:100-500 μM.Incubation Time:6-72 hours.Result:Increased the number of K562 apoptotic cells significantly.Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM.

Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss. Animal Model:SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn?/?).Dosage:200 mg/kg.Administration:Oral administration, b.i.d, at 09.00 and 17.00 daily.Result:Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.

AN-9 | Pivalyloxymethyl butyrate

Apoptosis

Apoptosis

GSK-3α| GSK-3β

——

——

122110-53-6

202.25

C10H18O4

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (494.44 mM)

CCCC(=O)OCOC(=O)C(C)(C)C

——

(-20℃)

With Ice Pack

≥ 2 years